Ansbert Gadicke Sells 20,277 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ansbert Gadicke sold 20,277 shares of the company’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $0.99, for a total value of $20,074.23. Following the transaction, the insider owned 5,044,760 shares of the company’s stock, valued at approximately $4,994,312.40. The trade was a 0.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Ansbert Gadicke also recently made the following trade(s):

• On Monday, December 1st, Ansbert Gadicke sold 60,917 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total transaction of $57,261.98.
• On Wednesday, November 26th, Ansbert Gadicke sold 60,733 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total transaction of $59,518.34.
• On Tuesday, November 25th, Ansbert Gadicke sold 42,533 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.92, for a total transaction of $39,130.36.
• On Monday, November 24th, Ansbert Gadicke sold 88,802 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total transaction of $87,025.96.
• On Friday, November 21st, Ansbert Gadicke sold 64,331 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.83, for a total transaction of $53,394.73.
• On Thursday, November 20th, Ansbert Gadicke sold 41,152 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total value of $36,625.28.
• On Wednesday, November 19th, Ansbert Gadicke sold 66,324 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total value of $62,344.56.
• On Tuesday, November 18th, Ansbert Gadicke sold 52,627 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.93, for a total value of $48,943.11.
• On Monday, November 17th, Ansbert Gadicke sold 57,061 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.95, for a total value of $54,207.95.
• On Friday, November 14th, Ansbert Gadicke sold 61,640 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.93, for a total value of $57,325.20.

Werewolf Therapeutics Stock Performance

Shares of HOWL traded down $0.08 during trading hours on Monday, reaching $0.92. 638,958 shares of the company’s stock traded hands, compared to its average volume of 503,042. The firm has a market capitalization of $44.50 million, a price-to-earnings ratio of -0.57 and a beta of 0.74. The business’s fifty day simple moving average is $1.48 and its two-hundred day simple moving average is $1.34. Werewolf Therapeutics, Inc. has a twelve month low of $0.60 and a twelve month high of $2.38. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 3.87.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.03. Analysts predict that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of institutional investors have recently bought and sold shares of HOWL. Jane Street Group LLC acquired a new position in shares of Werewolf Therapeutics in the 2nd quarter valued at about $409,000. Citadel Advisors LLC acquired a new stake in shares of Werewolf Therapeutics during the third quarter worth approximately $304,000. Vanguard Group Inc. boosted its holdings in shares of Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after purchasing an additional 109,796 shares during the period. Marshall Wace LLP purchased a new position in Werewolf Therapeutics during the second quarter valued at approximately $113,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in Werewolf Therapeutics in the 2nd quarter valued at approximately $92,000. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on HOWL shares. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Citigroup restated a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. Bank of America dropped their price target on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Zacks Research lowered Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 21st. Finally, JMP Securities decreased their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a report on Thursday, August 21st. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.